PTC shares to see pressure on ‘compelling’ uniQure data, says Citi

Citi expects shares of PTC Therapeutics (PTCT) to be under pressure after uniQure (QURE) reported Phase 1/2 date of its AMT130 gene therapy for Huntington’s disease, which demonstrated a 75% disease slowing at 36 months. The data are “very compelling” and set a “high bar” in Huntington’s, the analyst tells investors in a research note. Citi believes the AMT130 data raise questions as to whether PTC’s data for votoplam will be sufficient. It keeps a Neutral rating on PTC with a $50 price target. The stock in early trading is down 3% to $58.70.